May 27, 2015
Inhaled corticosteroids increased the incidence of pneumonia but reduced the risk for pneumonia-associated and overall mortality in patients with chronic obstructive pulmonary disease, according to the results of a recent systematic review and meta-analysis presented at the American Thoracic Society International Conference in Denver.
“Inhaled corticosteroids are currently recommended for use in patients with severe [chronic obstructive pulmonary disease (COPD)] and those with frequent exacerbations,” Ena Gupta, MD, MPH, of the University of Florida College of Medicine, and colleagues wrote. “The TORCH study and several other trials have shown increased incidence of pneumonia among patients using [inhaled corticosteroids (ICS)]. This meta-analysis was done to affirm the increased risk of pneumonia and then better define whether ICS use affected unadjusted pneumonia-associated and overall mortality.”